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Salivary gland tumors are rare, generally benign and affect 
mainly the parotid gland. Aim. The purpose of this study 
was to retrospectively analyze all cases of parotid tumors 
treated at our institution from 1953 to 2003. Methods. All 
patients with primary parotid tumors were selected; clinical 
and histopathological data were analyzed and described. 
Results. 600 cases of parotid tumors were selected; 369 were 
benign and 231 were malignant. Pleomorphic adenoma was 
the most frequent benign tumor. The most common malignant 
tumor was the mucoepidermoid carcinoma. Therapy in most 
cases consisted of parotidectomy. Adjuvant therapy - mainly 
radiotherapy - was used in some cases with malignant tumors. 
The incidences of local, regional and distant recurrences 
of malignant tumors were 10%, 8% and 9%. Conclusion. 
Patients with parotid tumors treated at our institution were 
mainly adults, with marginally more female patients. Benign 
tumors were mostly the pleomorphic adenoma, which were 
more frequent than malignancies. Most of the patients were 
treated by partial or total parotidectomy. Adjuvant therapy, 
mainly radiotherapy, was used in selected malignant cases.
Keywords: pleomorphic adenoma, mucoepidermoid 





Brazilian Journal of otorhinolaryngology 75 (4) July/august 2009
http://www.bjorl.org  /  e-mail: revista@aborlccf.org.br
INTRODUCTION
Salivary gland neoplasms are a rare group of tu-
mors; the annual incidence rate is 1 in 100,000 individual, 
comprising about 3% of all head and neck neoplasms.1 
The mean age of patients with salivary gland tumors is 45 
years, peaking in the sixth and seventh decades of life.2,3 
Benign salivary gland tumors occur more frequently in 
females, while malignant tumors are slightly more frequent 
in males.4,5
The parotid gland is the most frequent site - about 
70% of cases.4-6 About 80% of parotid tumors are benign, 
the most common being the pleomorphic adenoma (60% 
of parotid tumors), followed by Warthin’s tumor (10% of 
parotid tumors).4
The most common salivary gland malignancy is the 
mucoepidermoid carcinoma, which involves mostly the 
parotid gland, followed by the minor, submandibulary and 
sublingual salivary glands.5-7 The cystic adenoid carcinoma 
is the second most frequent malignancy in this area; other 
parotid tumors are acinar cell carcinomas, adenocarcinoma 
NOS, and the carcinoma ex pleomorphic adenoma.1
The main symptom in patients with parotid neoplas-
ms is a lump in the parotid area. Other symptoms such as 
pain, facial palsy and skin ulcers may manifest in malignant 
cases.8,9 The treatment of choice for benign and malignant 
parotid tumors is partial or total parotidectomy, according 
to the extent of the tumor.10 Radiotherapy may be useful in 
malignancies as adjuvant therapy; chemotherapy is rarely 
used.6,11,12 Local, regional and distance recurrence rates are 
40%, 15% and 11% each, and worsened the prognosis.6 
The purpose of this study was to assess the clinical and 
histological features of all patients with primary parotid tu-
mors treated at a single institution during a 50-year period.
SERIES AND METHOD
The Research Ethics Committee approved this study 
(protocol - 711/05). All primary parotid tumor cases treated 
at our institution from 1953 to 2003 were selected for this 
study. Cases were excluded when the patient file was not 
located, when information was lacking in the file, when 
paraffin blocks and slides were not available, or when 
patients were treated at another institution. Clinical data 
were gathered from medical files. A histological review 
of all cases was done based on the World Health Organi-
zation classification.13
RESULTS
The study sample consisted of 600 cases with the 
necessary information for analysis. There were 369 benign 
cases (60%) and 231 malignancies (40%). The mean age 
was 48.4 years. There were slightly more females in the 
sample (53%).
Benign
The most frequent benign tumors were the pleo-
morphic adenoma (66,5%) and Warthin’s tumor (25%). 
Other less frequent tumors were the basal cell adenoma, 
the oncocytoma and the myoepithelioma. Fifteen cases 
presented mesenchymal tumors: five lymphangiomas, 5 
neurofibromas, and 1 case each of lipoma, schwanoma, 
solitary fibrous tumor, giant cell tumor and meningioma 
(Table 1).
Table 1. Distribution of 369 benign tumors of the parotid gland trea-
ted at our institution, according to the histological type.
Histological type Number of cases Percentage
Pleomorphic adenoma 245 66,5%
Warthin’s tumor 93 25%
Basal cell adenoma 10 3%
Oncocytoma    4 1%
Myoepithelioma    2 0,5%
Mesenchymal tumors 15 4%
TOTAL 369 100%
The mean of patients with benign tumors was 47 
years; the peak incidence was the fifth decade of life. 
There were slightly more female patients - 55% of cases. 
In pleomorphic adenomas females comprised 62% of ca-
ses; in Warthin’s tumor, 65.5% of cases were males. The 
mean duration of complaints was 40 months; the main 
symptoms were lumps in the parotid area (98% of cases) 
and pain (11% of cases). The mean size of tumors was 
4 cm (ranging from 1 to 30 cm). Ten patients presented 
bilateral tumors (both parotid glands), all of which were 
diagnosed as Warthin’s tumor. All patients underwent sur-
gery; 330 cases (90%) underwent partial parotidectomy and 
38 cases (10%) underwent total parotidectomy. The facial 
nerve was fully preserved in 365 cases; at least one of its 
branches was sacrificed in 3 cases. The main postoperative 
complication was Frey’s syndrome (34 cases - 9%). Facial 
palsy was present in 34 cases; it was temporary in 28 cases 
and permanent in 6 cases. Local recurrence occurred in 
ten cases after 18 to 112 months (mean - 56 months), all 
of which with the pleomorphic adenoma.
Malignant
The most common malignancy was the mucoe-
pidermoid carcinoma, followed by the undifferentiated 
carcinoma, the cystic adenoid carcinoma, the adenocar-
cinoma NOS, the acinar cell carcinoma, the carcinoma ex 
pleomorphic adenoma, and the squamous cell carcinoma 
(Table 2). There were 24 non-epithelial origin malignan-
cies, of which 14 were lymphomas. The mean age of 
patients with malignant tumors was 50 years, peaking at 
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the sixth decade of life. Males comprised 52% of cases. 
The mean duration of complaints was 35 months; the main 
symptom was a lump in the parotid area (220 cases - 91%). 
Pain was reported in 30% of cases, facial palsy in 10% of 
cases, and trismus in 6% of cases. The mean diameter of 
tumors was 5.5 cm (ranging from 1 to 20 cm).
TNM staging was as follows: 23 cases were T1, 80 
cases were T2, 59 cases were T3, 70 cases were T4, and 
the primary tumor was not classified in 9 cases. Palpable 
lymph nodes were found in 39 cases: N1 in 21 cases, N2 
in 5 cases, and N3 in 10 cases. Three cases were classified 
as M1, all with lung metastases.
The main form of therapy was surgery; partial paro-
tidectomy was done in 36.3% of cases, total parotidectomy 
was done in 57% of cases, and extended parotidectomy 
was done in 6.7% of cases (including resection of adja-
cent structures such as muscle, mandible, ear and skin. 
The facial nerve was preserved in 72% of cases; it was 
partially resected in 9% of cases, and sacrificed in 19% 
of cases. Neck dissection, as well as parotidectomy, was 
done in 73 cases; metastatic lymph nodes were confirmed 
histopathologically in 38 cases. Postoperative radiotherapy 
was carried out in 72 cases; the mean dose was 4,800 Gy. 
Palliative therapy with radiotherapy only was done in 20 
cases; radiotherapy was associated with chemotherapy 
in 6 cases. Recurrences manifested in 48 patients (21%). 
Local recurrence occurred in 25 cases (10%); of these, 
13 cases were exclusively local recurrences, 4 cases also 
had regional recurrences, 5 cases had distance metastases, 
and 2 cases had both regional and distance metastases. 
Regional recurrence was seen in 19 cases (8%); of these, 
10 cases were exclusively regional recurrences, and 3 cases 
also had distance metastases. Distance metastases were 
identified in 21 cases (9%), exclusively so in 10 of these 
cases. The main organ involved in distance metastases 
was the lung (10 cases).
Our latest information shows that 90 patients died 
due to disease, 91 were alive and disease-free, 13 were 
alive with disease, 22 died due to other causes, and 15 
were lost to follow-up.
DISCUSSION
The parotid gland is the main site of salivary gland 
tumors.2,8 About 64 to 80% of all primary salivary gland 
epithelial tumors involve the parotid gland, mostly located 
in the superficial lobe.14 Our sample comprised 600 cases 
of benign and malignant primary parotid gland tumors.
The incidence of salivary gland tumors peaks in 
the sixth and seventh decades of life; the mean age was 
46 years3. Satko et al.15 reported a mean age of 53 years 
(ranging from 2 to 87 years). Most studies show that the 
mean age is higher in malignant tumors (about 55 years) 
compared to benign tumors (about 45 years).2,8,16 Our re-
sults confirm these findings; the mean age in our sample 
was 48.4 years - 47 years for benign tumors and 50 years 
for malignancies.
Most of the reviews of salivary gland tumor series 
show that there are more females than males in both 
benign and malignant cases.8,14,17 This varies depending 
on the type of tumor; for example, males predominate in 
Warthin’s tumor.2 Ito et al.16 found that there were more 
Table 2. Distribution of 231 malignant tumors of the parotid gland treated at our institutions, according to the histological type.
Histological type Number of cases Percentage
Mucoepidermoid carcinoma 67 29%
Undifferentiated carcinoma 33 13,5%
Cystic adenoid carcinoma 27 11%
Adenonocarcinoma NOS 22 9%
Acinar cell carcinoma 20 8%
Carcinoma ex pleomorphic adenoma 19 8%
Squamous cell carcinoma 15 6%
Basal cell adenocarcinoma 5 3%
Salivary duct carcinoma 4 2%
Lymphoepithelial carcinoma 2 1%
Epithelial-Myoepithelial carcinoma 1 0,5%
Oncocytic carcinoma 1 0,5%
Myoepithelial carcinoma 1 0,5%
Lymphoma 14 6%
Non-lymphoid mesenchymal tumor 4 2%
TOTAL 231 100%
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female patients in benign tumors (58.5%), whereas males 
predominated in malignant tumors (52.2%). We found a 
slight female predominance (53% of cases), with 55% in 
benign tumor cases. In malignant tumors, however, males 
predominated (52% of cases).
The main complaint of patients with parotid tu-
mors was a lump in the parotid area. About 50% parotid 
malignant tumors had clinical findings that were similar 
to those of benign tumors, such as slow growth, mobility 
over underlying tissues, and absence of symptoms. The 
remaining 50%, however, manifested signs of malignancy, 
such as facial palsy, pain, trismus, and no mobility.18 Most 
of our benign tumor cases presented a lump in the parotid 
area. In malignant tumor cases, the parotid volume was 
increased and 34% of patients also manifested pain, facial 
palsy and/or trismus.
The pleomorphic adenoma and Warthin’s tumor are 
the most common benign tumors.3,16 Our data show that 
the pleomorphic adenoma and Warthin’s tumor comprised 
66.5% and 25% of cases each. The percentage of Warthin’s 
tumors in our study was high compared to other series 
of parotid tumors, in which this number generally ranges 
from 9% to 15%.8,14,15,19
Malignant tumors comprise about 15 to 30% of 
parotid tumors; the most commonly reported of these is 
the mucoepidermoid carcinoma, followed by the cystic 
adenoid carcinoma.1,8,16 Wahlberg et al.’s20 review of 2,062 
parotid carcinoma cases revealed that the mucoepidermoid 
carcinoma was the most common tumor, followed by 
the adenocarcinoma NOS, the acinar cell carcinoma, the 
cystic adenoid carcinoma, the carcinoma ex pleomorphic 
adenoma, and the undifferentiated carcinoma. We also 
found among our series of malignant tumors that the mu-
coepidermoid carcinoma was the most common tumor, 
followed by the undifferentiated carcinoma, the cystic ade-
noid carcinoma, the adenocarcinoma NOS, the acinar cell 
carcinoma, and the carcinoma ex pleomorphic adenoma.
The treatment of choice for benign tumors of the pa-
rotid gland is parotidectomy, preserving the facial nerve.21 
Generally, partial parotidectomy is done in tumors limited 
to the superficial lobe, which is fully resected. Removal 
of the whole parotid lobe aims to attain adequate surgical 
margins and avoid rupture of the capsule, which reduces 
the recurrence rate.22 Total parotidectomy in benign tumors 
is done when the deep lobe of the parotid is involved.23 
Rupture of the capsule during surgical resection and 
positive microscopic margins may lead to recurrences.24 
Parotidectomy was done in all of our cases of benign tu-
mors; only 10 cases had local recurrences. The treatment 
of choice for parotid malignant tumors is partial or total 
parotidectomy; the facial nerve is preserved if possible.10 
Adjuvant radiotherapy has been shown to be effective for 
improving local control and increased survival.12,25 Local, 
regional and distance recurrence rates for parotid malig-
nant tumors are about 40%, 15% and 11%  each; in these 
cases, the prognosis is worse.6,26 Parotidectomy was done 
in most of our patients with malignant tumors; adjuvant 
therapy was used in some cases. Recurrence rates were 
10% (local), 8% (regional), and 9% (distance), lower than 
most of published results in the international literature.
CONCLUSION
Benign tumors were more frequent in a series of 600 
cases of parotid tumors. The pleomorphic adenoma was 
the most common tumor. The mucoepidermoid carcinoma 
was the most common malignant tumor. Parotidectomy 
was the main form of therapy; radiotherapy was reserved 
for specific malignant tumor cases. Recurrences of any type 
occurred in 48 patients (21% of cases) during follow-up.
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